Angiogenesis	O
-	O
a	O
novel	O
therapeutic	O
approach	O
for	O
ischemic	O
heart	B-Organ
disease	O
.	O

Angiogenesis	O
is	O
the	O
biologic	O
process	O
of	O
forming	O
new	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
.	O

Undoubtedly	O
,	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
growth	O
regulation	O
is	O
a	O
vital	O
aspect	O
in	O
health	O
and	O
disease	O
.	O

Under	O
physiological	O
conditions	O
,	O
angiogenesis	O
is	O
regulated	O
by	O
local	O
balance	O
between	O
endogenous	O
stimulators	O
and	O
inhibitors	O
of	O
this	O
process	O
.	O

In	O
many	O
diseases	O
state	O
body	B-Organism_subdivision
loses	O
control	O
over	O
angiogenesis	O
.	O

Angiogenesis	O
-	O
dependent	O
diseases	O
result	O
when	O
new	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
either	O
grow	O
excessively	O
or	O
insufficiently	O
.	O

Insufficient	O
angiogenesis	O
occurs	O
in	O
diseases	O
such	O
as	O
coronary	B-Multi-tissue_structure
artery	I-Multi-tissue_structure
disease	O
,	O
stroke	O
and	O
chronic	O
wounds	B-Pathological_formation
.	O

Myocardial	B-Multi-tissue_structure
ischemia	O
both	O
acute	O
and	O
chronic	O
has	O
been	O
clearly	O
shown	O
to	O
stimulate	O
angiogenesis	O
in	O
many	O
experimental	O
models	O
.	O

Therapeutic	O
angiogenesis	O
is	O
the	O
biological	O
agents	O
or	O
bioactive	O
material	O
to	O
stimulate	O
the	O
growth	O
of	O
new	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
.	O

Traditional	O
coronary	B-Multi-tissue_structure
revascularization	O
therapies	O
such	O
as	O
coronary	B-Multi-tissue_structure
angioplasty	O
or	O
bypass	B-Multi-tissue_structure
graft	I-Multi-tissue_structure
surgery	O
,	O
act	O
by	O
restoring	O
blood	B-Organism_substance
flow	O
through	O
the	O
preexisting	O
coronary	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
.	O

One	O
limitation	O
of	O
these	O
approaches	O
,	O
however	O
,	O
may	O
be	O
the	O
failure	O
to	O
normalize	O
myocardial	B-Multi-tissue_structure
perfusion	O
,	O
due	O
to	O
the	O
concomitant	O
presence	O
or	O
small	O
of	O
resistance	O
vessel	B-Multi-tissue_structure
disease	O
.	O

In	O
contrast	O
,	O
therapeutic	O
angiogenesis	O
is	O
based	O
on	O
the	O
concept	O
that	O
coronary	B-Multi-tissue_structure
collateral	I-Multi-tissue_structure
development	O
may	O
be	O
stimulated	O
by	O
pharmacological	O
or	O
molecular	O
means	O
and	O
can	O
limit	O
myocardial	B-Multi-tissue_structure
ischemia	O
.	O

Studies	O
,	O
both	O
in	O
human	O
and	O
animal	O
models	O
support	O
the	O
notion	O
that	O
,	O
various	O
angiogenic	O
growth	O
factors	O
and	O
progenitor	B-Cell
cells	I-Cell
can	O
enhance	O
new	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
,	O
recombinant	O
proteins	O
and	O
bone	B-Cell
marrow	I-Cell
stem	I-Cell
cells	I-Cell
are	O
currently	O
used	O
therapeutic	O
stimulators	O
for	O
angiogenesis	O
.	O

As	O
coronary	B-Multi-tissue_structure
artery	I-Multi-tissue_structure
disease	O
is	O
the	O
major	O
cause	O
of	O
death	O
in	O
the	O
developed	O
societies	O
and	O
also	O
an	O
emerging	O
health	O
problem	O
in	O
developing	O
countries	O
like	O
Bangladesh	O
therapeutic	O
angiogenesis	O
may	O
provide	O
hope	O
as	O
a	O
new	O
treatment	O
modality	O
for	O
ischemic	O
heart	B-Organ
disease	O
with	O
or	O
in	O
place	O
of	O
current	O
therapies	O
.	O

